Compare TEVA & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | IQV |
|---|---|---|
| Founded | 1901 | 1982 |
| Country | Israel | United States |
| Employees | 32842 | 93000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5B | 28.6B |
| IPO Year | N/A | 2013 |
| Metric | TEVA | IQV |
|---|---|---|
| Price | $31.27 | $172.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | $38.63 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 4.8M | 1.2M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 7.84 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | N/A | $6.78 |
| Revenue Next Year | $3.24 | $5.88 |
| P/E Ratio | $28.19 | ★ $22.66 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $13.04 | $134.65 |
| 52 Week High | $37.35 | $247.05 |
| Indicator | TEVA | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 49.96 |
| Support Level | $30.70 | $159.42 |
| Resistance Level | $31.99 | $193.26 |
| Average True Range (ATR) | 0.88 | 6.11 |
| MACD | 0.33 | 1.32 |
| Stochastic Oscillator | 82.96 | 54.41 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.